These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31563242)

  • 1. Trough Level of Mycophenolic Acid Did Not Affect De Novo DSA Development in Kidney Transplantation.
    Masaki N; Iwadoh K; Tonsho M; Koyama I; Nakajima I; Fuchinoue S
    Transplant Proc; 2019 Oct; 51(8):2624-2628. PubMed ID: 31563242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimum mycophenolic acid levels are associated with donor-specific antibody formation.
    Filler G; Todorova EK; Bax K; Alvarez-Elías AC; Huang SH; Kobrzynski MC
    Pediatr Transplant; 2016 Feb; 20(1):34-8. PubMed ID: 26589470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
    Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
    Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Long-Term Survival in Kidney Transplant Recipients with Donor-Specific HLA Antibodies After Mycophenolic Acid Escalation.
    Rebellato LM; Parker K; Everly MJ; Briley KP; Kendrick W; Kendrick S; Haisch CE; Terasaki PI; Bolin P
    Clin Transpl; 2014; ():137-42. PubMed ID: 26281138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
    Narumi S; Watarai Y; Goto N; Hiramitsu T; Tsujita M; Okada M; Futamura K; Tomosugi T; Nishihira M; Sakamoto S; Kobayashi T
    Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of antibody removal following proteasome inhibitor-based therapy.
    Everly MJ; Terasaki PI; Trivedi HL
    Transplantation; 2012 Mar; 93(6):572-7. PubMed ID: 22262128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L; Ehrich JH; Offner G
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
    Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
    Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
    Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
    Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U; Lindner S; Vollandt R; Sperschneider H; Balogh A
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.